This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sergott RC, Amorelli GM, Baranello G, Barreau E, Beres S, Kane S, et al. FIREFISH, SUNFISH, JEWELFISH Working Groups. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy. Ann Clin Transl Neurol. 2021;8:54–65. Epub 2020 Nov 24
Szollosi A, Donkin C. Arrested theory development: the misguided distinction between exploratory and confirmatory research. Perspect Psychol Sci. 2021;16:717–24. Epub 2021 Feb 16
Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384:915–23. FIREFISH Working GroupEpub 2021 Feb 24
Darras BT, Masson R, Mazurkiewicz-Bełdzińska M, Rose K, Xiong H, Zanoteli E, et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385:427–35. FIREFISH Working Group
Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16:29.
Lash TL, Vandenbroucke JP. Should preregistration of epidemiologic study protocols become compulsory? Reflections and a counterproposal. Epidemiology. 2012;23:184–8.
Harvey LA. Trial registration: a pre-requisite for publication and an ethical responsibility. Spinal Cord. 2017;55:329–30.
Vandenbroucke JP. Preregistration of epidemiologic studies: an ill-founded mix of ideas. Epidemiology. 2010;21:619–20.
Acknowledgements
The Journal Club is a collaboration between the American Academy of Pediatrics – Section on Neonatal Perinatal Medicine and the International Society for Evidence-based Neonatology (EBNEO.org).
Author information
Authors and Affiliations
Contributions
All authors contributed equally towards initial conception and design, data analysis and interpretation, and manuscript composition and final approval.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gaffar, S., Cayabyab, R. & Ramanathan, R. Is treatment with oral risdiplam effective and well-tolerated for infants with spinal muscular atrophy type 1?. J Perinatol 42, 689–691 (2022). https://doi.org/10.1038/s41372-021-01301-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41372-021-01301-5